Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During 'Live' Case at the Paris Cardiovascular Interventions Course (Francop... (MD Service de Cardiologie CliniqueTurin ...)

HOME >> BIOLOGY >> TECHNOLOGY

Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During 'Live' Case at the Paris Cardiovascular Interventions Course (Francophone) 2008

Date:10/1/2008

MD, Service de Cardiologie, Clinique Turin, Paris, France. "For the live case, we want to really test the CATANIA(TM) Stent's capabilities in a challenging anatomy, because of the clinical evidence that Polyzene(R)-F nanocoating prevents thrombosis, restenosis and reocclusion. Based on my experience, I believe the CATANIA(TM) Stent is an ideal choice for treating coronary artery disease, including chronic total occlusions."

The rapid-exchange, cobalt-chromium CATANIA(TM) Stent features a modified open-cell design and is available in 60 sizes in lengths from 8mm to 38mm and in diameters, from 2.0 to 4.0mm. The CATANIA(TM) Stent does not contain any drugs, off-loaded materials or biological substitutes. The proprietary nanothin, highly lubricious Polyzene(R)-F is a synthesized, inorganic, biocompatible polymer that is anti-thrombotic, anti-inflammatory, bacterial-resistant, and essentially cloaks the device's presence from the body to promote healthy endothelial cell growth without stimulating platelet activation. This unique combination of stent and surface treatment effectively creates a new and different class of stent that does not require long-term dual anti-platelet therapy.

"It is exceptionally gratifying that Dr. Corcos and Dr. Ochiai selected to showcase the abilities of the CATANIA(TM) Stent in such an important, and difficult-to-treat live case, because we design all of our products from the ground up using direct feedback from the physicians who use them," said Thomas A. Gordy, President and Chief Executive Officer, CeloNova BioSciences, Inc. "We are looking forward to presenting the CATANIA(TM) long-term, First-In-Man data on the world stage later this month during the Transcatheter Therapeutics (TCT) annual meeting in Washington, DC."

For more information about CeloNova BioSciences' products and Polyzene(R)-F technology, visit http://www.celonova.com .

About CeloNova BioScien
'/>"/>

SOURCE CeloNova BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Diageo Sponsors Medical Society of the State of New Yorks Physicians Training Program
2. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
3. Top Health Care Economists and Physician-Innovators Discuss Value of Medical Technology at AdvaMed 2007 Conference
4. Cynthia Haines, M.D., Named Managing Editor of Physicians Briefing News Wire
5. Young Physicians Demanding Advanced Laparoscopic Energy Instruments
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
8. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
9. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
10. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
11. Hot Information for Physicians Treating Vasomotor Symptoms During the Menopausal Transition

Post Your Comments:

(Date:12/15/2009)... -- Epeius Biotechnologies Corporation, an emerging leader in ... validation of the cutting-edge science behind its lead ... the world rediscovered the Cyclin G1 gene ... pathogenesis and disease progression, and thus a prime ... NIH National Cancer Institute investigating the role of ...

(Date:12/15/2009)... WALTHAM, Mass., Dec. 15 Repligen Corporation ... Company has received $731,000 in research funding to ... Friedreich,s ataxia from the Muscular Dystrophy Association (MDA). ... preclinical GLP toxicology testing and GMP manufacture of ... Support from the MDA not only provides important ...

(Date:12/15/2009)... Reportlinker.com announces that a new ... catalogue: ,, The Future of ... 2015, Pipeline Analysis and Reimbursement ... ,, Summary ,, The author ... of Orphan Diseases Therapeutics - Market Forecasts ...

(Date:12/15/2009)... WILMINGTON, Del. and CHARLOTTESVILLE, Va., Dec. 15 ... ) and the University of Virginia (UVa) ... entered into a strategic research collaboration to ... coronary artery disease (CAD) with a secondary ... (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) ,, The ...

[0] Scientists Rediscover Gene Target for Cancer Therapy [0] Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program [0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement [0] AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease

... DCGN ) today announced that it will report its third ... on Monday, November,5, after the close of the market in ... conference call to discuss these results and recent,operating highlights on ... The webcast can be accessed through the Investors page of ...

... Rises 6%; Clinical Diagnostics Grows 9.4%; On Target to ... Achieve Full ... BEC ), a leading developer, manufacturer and marketer of,products that ... September 30, 2007 results. Total,revenue of $669 million was up 6.0% ...

... Ventaira Pharmaceuticals,announced today that Battelle, a science ... assist Ventaira in closing its,operations. Financial terms of ... be working with Battelle to transition our assets. ... explore employment,opportunities for our employees," said Leslie Williams, ...

deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results Beckman Coulter Announces Third Quarter 2007 Results Ventaira Pharmaceuticals Announces Acquisition of Assets by Battelle

(Date:12/16/2009)... Signal Hill, CA Tom Bowman, an expert ... of Bowman Global Change, has developed a series of ... Panel on Climate Change (IPCC) report for public audiences. ... scientific information they need to make informed decisions about ... new format as a means to clearly and accurately ...

(Date:12/16/2009)... YORK, Dec. 1 iQor, a global provider ... the 2009 InfoWorld 100 Awards Top 100 ... TeQ21. This was the first submission for iQor. ,, ... list of companies," said Vikas Kapoor, president and CEO ... do business, allowing us to work faster, smarter and ...

(Date:12/16/2009)... REDWOOD CITY, Calif., Dec. 2 ... and authentication solutions, today announced an agreement ... of its DigitalPersona biometric fingerprint technology on ... U.are.U® 4500HD offering allows point-of-sale applications to ... that specific transactions can be linked to ...

Breaking Biology News(10 mins):Bowman creates graphic translation of climate change data 2 iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2 DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2 The Tile Doctor Launches Inaugural Product Line 14086 1 The Tile Doctor Launches Inaugural Product Line 14086 2 The Tile Doctor Launches Inaugural Product Line 14086 3 Video 3A Members of Congress Receive Legislative Awards From National Amputee Organizations 57326 1 Video 3A Members of Congress Receive Legislative Awards From National Amputee Organizations 57326 2 Video 3A Members of Congress Receive Legislative Awards From National Amputee Organizations 57326 3 Premion First in Australia to Treat Cancer Patients with RapidArc 28R 29 Radiotherapy Technology from Varian Medical Systems 57324 1 Premion First in Australia to Treat Cancer Patients with RapidArc 28R 29 Radiotherapy Technology from Varian Medical Systems 57324 2 Premion First in Australia to Treat Cancer Patients with RapidArc 28R 29 Radiotherapy Technology from Varian Medical Systems 57324 3

[0] Bowman creates graphic translation of climate change data [0] iQor Named to InfoWorld 100 List of Top IT Projects of 2009 [0] DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems

... person,s body mass consisting of skeletal muscle, chronic inflammation ... the limbs can result in significant physical impairment. ... health professor Kimberly Huey, past research has demonstrated that ... with reduced expression of certain pro-inflammatory cytokines, in vitro, ...

... be published by Springer as of January 2009. The ... previously published by Wiley-Blackwell, is respected internationally for the ... broad range of subject areas relevant to fisheries science. ... Fisheries Science includes original and review articles ...

... 2008. The first 5-year forest inventory report for California,s ... public: California,s Forest Resources, 2001-2005: Five-Year Forest Inventory and ... report:, , Forests cover about a third of ... managed. , Houses built in the wildland-urban interface account ...

Other Biology News:Vitamin E shows possible promise in easing chronic inflammation 2 Vitamin E shows possible promise in easing chronic inflammation 3 Forest inventories in California include more than trees 2 Forest inventories in California include more than trees 3

Vitamin E shows possible promise in easing chronic inflammation Springer to publish Fisheries Science as of 2009 Forest inventories in California include more than trees

... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...

Mouse monoclonal antibody raised against a partial recombinant CHD8. NCBI Entrez Gene ID = CHD8...

Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...

... raised against a partial recombinant NFKBIB. ... 145 a.a) partial recombinant protein with GST tag. ... Accession: BC015528 ... OMIM: 604495, GeneID: ...

Biology Products:

hERG-CHO K1 Recombinant Cell Line from Upstate Mouse Anti-Human CHD8 Monoclonal Antibody, Unconjugated, Clone 2C8 from Abnova Corporation Mouse Anti-Human PASK Monoclonal Antibody, Unconjugated, Clone 6D10 from Abnova Corporation Mouse Anti-NFKBIB Monoclonal Antibody, Unconjugated, Clone 2B11 from Abnova Corporation

Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During 'Live' Case at the Paris Cardiovascular Interventions Course (Francop...(MD Service de Cardiologie CliniqueTurin ...)